# MNPR-101 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mnpr-101

> MNPR-101, sponsored by Monopar Therapeutics (MNPR): 4 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | MNPR-101 |
| Codes | MNPR-101 |
| Sponsor | Monopar Therapeutics (MNPR) https://sec-api.dev/companies/mnpr/catalysts |
| Indications | advanced cancers, and in april 2024, we launched the phase 1 trial |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Feb 2024: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: advanced cancers, and in April 2024, we launched the Phase 1 trial.
- First seen 2025-03-31, last confirmed 2026-11-12.
- SEC Form 10-Q (accession 0001437749-26-036384): "In February 2024, we received regulatory clearance in Australia to commence a first-in-human Phase 1 imaging and dosimetry clinical trial with our novel radiopharmaceutical imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) in patients with advanced cancers, and in April 2024, we launched the Phase 1 trial." https://www.sec.gov/Archives/edgar/data/1645469/000143774926036384/mnpr20260930_10q.htm
- SEC Form 10-Q (accession 0001437749-26-027164): "In February 2024, we received regulatory clearance in Australia to commence a first-in-human Phase 1 imaging and dosimetry clinical trial with our novel radiopharmaceutical imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) in patients with advanced cancers, and in April 2024, we launched the Phase 1 trial." https://www.sec.gov/Archives/edgar/data/1645469/000143774926027164/mnpr20260630_10q.htm
- SEC Form 10-Q (accession 0001437749-26-016982): "In February 2024, we received regulatory clearance in Australia to commence a first-in-human Phase 1 imaging and dosimetry clinical trial with our novel radiopharmaceutical imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) in patients with advanced cancers, and in April 2024, we launched the Phase 1 trial." https://www.sec.gov/Archives/edgar/data/1645469/000143774926016982/mnpr20260331_10q.htm
- SEC Form 10-K (accession 0001437749-26-010025): "In February 2024, we received regulatory clearance in Australia to commence a first-in-human Phase 1 imaging and dosimetry clinical trial with our novel radiopharmaceutical imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) in patients with advanced cancers, and in April 2024, we launched the Phase 1 trial." https://www.sec.gov/Archives/edgar/data/1645469/000143774926010025/mnpr20251231_10k.htm
- SEC Form 10-Q (accession 0001437749-25-034617): "In February 2024, we received regulatory clearance in Australia to commence a first-in-human Phase 1 imaging and dosimetry clinical trial with our novel radiopharmaceutical imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) in patients with advanced cancers, and in April 2024, we launched the Phase 1 trial." https://www.sec.gov/Archives/edgar/data/1645469/000143774925034617/mnpr20250930_10q.htm
- SEC Form 10-Q (accession 0001437749-25-026042): "In February 2024, we received regulatory clearance in Australia to commence a first-in-human Phase 1 imaging and dosimetry clinical trial with our novel radiopharmaceutical imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) in patients with advanced cancers, and in April 2024, we launched the Phase 1 trial." https://www.sec.gov/Archives/edgar/data/1645469/000143774925026042/mnpr20250630_10q.htm
- SEC Form 10-Q (accession 0001437749-25-016263): "In February 2024, we received regulatory clearance in Australia to commence a first-in-human Phase 1 imaging and dosimetry clinical trial with our novel radiopharmaceutical imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) in patients with advanced cancers, and in April 2024, we launched the Phase 1 trial." https://www.sec.gov/Archives/edgar/data/1645469/000143774925016263/mnpr20250331_10q.htm
- SEC Form 10-K (accession 0001437749-25-009979): "In February 2024, we received regulatory clearance in Australia to commence a first-in-human Phase 1 imaging and dosimetry clinical trial with our novel radiopharmaceutical imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) in patients with advanced cancers, and in April 2024, we launched the Phase 1 trial." https://www.sec.gov/Archives/edgar/data/1645469/000143774925009979/mnpr20241231_10k.htm

### Apr 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-03-31, last confirmed 2026-03-27.
- SEC Form 10-K (accession 0001437749-26-010025): "In April 2024, we launched the Phase 1 trial, and in July 2024, we announced the enrollment of our first patient." https://www.sec.gov/Archives/edgar/data/1645469/000143774926010025/mnpr20251231_10k.htm
- SEC Form 10-K (accession 0001437749-25-009979): "In April 2024, we launched the Phase 1 trial, and in July 2024, we announced the enrollment of our first patient." https://www.sec.gov/Archives/edgar/data/1645469/000143774925009979/mnpr20241231_10k.htm

### December 5, 2024: trial start

- Status: completed. Date confidence: exact.
- First seen 2024-12-06, last confirmed 2025-03-31.
- SEC Form 8-K (accession 0001437749-24-036825): "On December 5, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing that a first patient was dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu." https://www.sec.gov/Archives/edgar/data/1645469/000143774924036825/mnpr20241205_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-24-036825): "Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu" https://www.sec.gov/Archives/edgar/data/1645469/000143774924036825/ex_754335.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-009982): "Dosed first patient with MNPR-101-Lu in December 2024" https://www.sec.gov/Archives/edgar/data/1645469/000143774925009982/ex_795025.htm

### early 2026: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2025-08-12, last confirmed 2025-08-12.
- Press release filed with the SEC (EX-99) (accession 0001437749-25-026043): "Examples of these forward-looking statements include statements concerning: that Monopar is responsible for advancing the program commercially; that Monopar is preparing to submit an NDA to the FDA in early 2026; that Monopar continues its preclinical work with MNPR-101-Ac with the plan to enter the clinic in the future; and that Monopar expects that its current funds will be sufficient to continue operations at least through December 31, 2026." https://www.sec.gov/Archives/edgar/data/1645469/000143774925026043/ex_849537.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mnpr-101.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MNPR-101 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mnpr-101

```bibtex
@misc{secapidev_pdufa_mnpr_101_20261116,
  title        = {MNPR-101 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mnpr-101}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mnpr_101_20261116","title":"MNPR-101 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mnpr-101","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
